Biocon Limited share price

Biocon Limited, together with its subsidiaries, manufactures biotechnology products and offers research services in India, the United States, Ireland, rest of the European Union, and internationally. It operates through Generics; Biosimilars; and Contract Research, Development and Manufacturing Organization (CRDMO) segments. The company offers generic formulations and API products, including cardiovascular, anti-diabetics, obesity, central nervous system, anti-cancer/oncology, multiple sclerosis, immunosuppressants, and specialty molecules; and biosimilars products for oncology, diabetes, and immunology therapeutic areas. It also provides integrated discovery, development, and manufacturing…Read more

Website NSE हिंदी में BSE

HealthcareBiotechnologyNifty 500 Nifty Midcap 150NSE: BIOCONISIN INE376G01013

16 Oct 2026, 3:28 PM IST₹349.20▼ 2.80 (0.80%)

Market Cap₹ 57,190 Cr.
Current Price₹ 349.20
High / Low₹ 447 / 338
Stock P/E103.3
Book Value₹ 210
Dividend Yield0.14 %
ROCE2.8 %
ROE1.40 %
Face Value₹ 5.0

More figures (10)

EPS (TTM)₹ 3.38
Price / Book1.66
OPM10.3 %
Debt / Equity0.45
Sales growth (5Y)19.0 %
Profit growth (5Y)-15.3 %
Promoter holding48.1 %
EV / EBITDA19.7
Beta0.32
All-time high₹ 488

Price chart

Price on NSE 50 DMA 200 DMA Volume

Returns	1M	3M	6M	YTD	1Y	3Y CAGR	5Y CAGR
BIOCON	-6.73%	-20.76%	-0.44%	-11.35%	-2.51%	+11.16%	+0.39%
Nifty 50	-0.31%	-3.85%	-4.34%	-11.42%	-9.53%	+5.46%	+4.76%

Price returns only (dividends not included). Prices from NSE via Yahoo Finance; may be delayed.

Quick take

Biocon Limited is in the Biotechnology industry (Healthcare), with a market value of ₹57,190 crore.
It trades at 103.3 times its last 12 months' earnings and 1.7 times book value.
Revenue grew 19.0% a year over the last 5 years, profit -15.3% a year.
Return on equity was 1.4% and return on capital employed 2.8% in the latest year.
Debt was 0.45 times shareholders' equity.
The share price is 21.9% below its 52-week high and down 2.5% over one year.
Promoters and insiders hold about 48.1%; institutions about 31.8%.

Pros

Sales have grown 19.0% a year over the last 5 years.
Institutional (FII + DII) holding has risen by 9.5 points over 3 years.

Cons

Return on equity has been low: 3.9% on average over the last 3 years.
Interest cover is thin: operating earnings are 1.9 times the interest cost.
Profit growth has been weak: -15.3% a year over the last 5 years.
Promoter holding has fallen by 15.96 points over 3 years, to 44.68%.
Other income makes up 66% of profit before tax.

Pros and cons are generated automatically from the reported figures. They are observations, not a recommendation to buy or sell.

AI analysis

Plenitude AI reads the figures on this page and explains them in plain language. It does not say whether to buy or sell.

About Biocon Limited

Employees: 16,447
Head office: Bengaluru
NSE industry: Healthcare

HealthcareHealthcareBiotechnology

Part ofNifty 500 Nifty Midcap 150

S.No.	Company	CMP ₹	P/E	Mar Cap ₹ Cr	Div Yld %	NP Qtr ₹ Cr	Qtr Profit Var %	Sales Qtr ₹ Cr	Qtr Sales Var %	ROCE %	ROE %	P/B	OPM %	Debt / Eq	Prom. Hold. %	Sales ₹ Cr	Sales Var 3Yrs %
1.	Biocon	349.20	103.3	57,190	0.14	137	53.36	4,336	10.00	2.8	1.4	1.66	10.3	0.45	48.12	16,927	19.0
2.	Anthem Biosciences	822.15	81.0	46,330	0.24	120	-11.67	418	-22.58	26.8	21.7	15.18	33.2	0.02	80.89	2,124	26.2
3.	OneSource Specialty Pharma	1,407.80	—	16,144	0.00	25	—	449	37.20	0.3	-1.3	2.77	-0.4	0.26	35.49	1,422	232.4
4.	Concord Biotech	1,339.00	46.1	14,008	0.56	58	30.96	257	26.23	16.7	13.6	6.94	29.1	0.00	72.48	1,046	8.0
5.	Dishman Carbogen Amcis	149.83	146.9	2,349	0.00	-58	-347.24	678	-4.29	2.7	1.6	0.35	6.9	0.46	69.30	2,932	7.5
	Median: 5 Co.	822.15	92.2	16,144	0.14	58	9.64	449	10.00	2.8	1.6	2.77	10.3	0.26	69.30	2,124	19.0

Companies in the same industry; the median covers every company in it that we hold figures for. Tap a heading to sort. Sorting and comparing are ways to explore data, not recommendations.

Quarterly Results

Consolidated figures in ₹ crore /

₹ Cr	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	3,423	3,462	3,954	3,917	3,433	3,590	3,821	4,417	3,942	4,296	4,173	4,517	4,336
YOY Sales Growth %	59.97%	49.26%	34.43%	3.79%	0.30%	3.70%	-3.35%	12.76%	14.83%	19.64%	9.20%	2.25%	10.00%
	2,708	2,721	3,027	3,001	2,813	2,905	3,070	3,339	3,193	3,460	3,340	3,496	3,489
Material Cost %	35%	33%	31%	34%	34%	33%	36%	33%	36%	36%	32%	31%	34%
Employee Cost %	17%	18%	18%	19%	22%	22%	21%	18%	21%	21%	21%	20%	21%
Other Expenses %	27%	28%	27%	24%	25%	26%	24%	24%	24%	24%	27%	26%	25%
Operating Profit	714	742	927	916	620	685	752	1,078	749	835	834	1,020	847
OPM %	21%	21%	23%	23%	18%	19%	20%	24%	19%	19%	20%	23%	20%
	94	158	566	49	1,135	33	35	37	80	93	117	53	55
Exceptional items		-24	21	-9	32	26	18	20		-12	-293	-80	-14
Interest	233	248	267	227	236	226	223	212	277	272	210	232	213
Depreciation	358	389	415	407	405	420	425	436	455	473	515	513	547
Profit before tax	217	239	832	322	1,146	98	156	487	97	171	-68	248	128
	16%	17%	7%	30%	25%	72%	48%	6%	8%	22%		20%	-7%
Current tax	43	52	83	136	225	24	114	6	67	59	67	251	116
Deferred tax	-9	-11	-28	-40	58	47	-39	21	-59	-21	-83	-202	-125
	149	173	753	223	862	27	81	459	89	133	-52	199	137
Profit from associates	-33	-24	-24	-3
Minority share	48	47	93	87	202	43	56	115	58	48	-196	73	-4
Profit to shareholders	101	126	660	136	660	-16	25	345	31	85	144	126	141
YOY Profit Growth %	-11.05%	111.12%		-46.22%	478.78%	-84.31%	-89.23%	106.10%	-89.65%	390.04%	-163.87%	-56.77%	53.36%
EPS in Rs	0.85	1.05	5.52	1.13	5.51	-0.13	0.21	2.88	0.26	0.66	1.08	0.79	0.87
Raw filing

₹ Cr	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	513	519	563	533	511	525	563	644	537	583	621	605	625
YOY Sales Growth %	16.19%	5.97%	1.41%	5.11%	-0.51%	1.29%		20.88%	5.19%	11.02%	10.39%	-6.07%	16.27%
	441	452	492	480	466	488	532	582	517	530	548	525	564
Material Cost %	43%	42%	44%	47%	42%	45%	47%	49%	47%	46%	44%	46%	46%
Employee Cost %	21%	22%	21%	22%	23%	24%	23%	19%	23%	22%	20%	15%	21%
Other Expenses %	22%	24%	22%	21%	26%	24%	24%	22%	25%	24%	25%	26%	23%
Operating Profit	72	67	71	52	45	38	31	62	21	53	73	79	61
OPM %	14%	13%	13%	10%	9%	7%	6%	10%	4%	9%	12%	13%	10%
	36	70	49	39	42	74	64	63	61	134	75	50	65
Exceptional items	20	-5					608				-196	-19
Interest	48	55	56	40	55	60	65	57	56	67	2	17	17
Depreciation	30	31	31	30	31	31	34	33	33	34	34	36	38
Profit before tax	50	46	33	22	1	21	604	35	-8	86	-85	57	70
	6%	25%	27%	36%	18%	85%	3%	39%		17%		11%	25%
Current tax	4	11	12	-9	2	-7	8	27	1	3	9	-1	17
Deferred tax	-1		-3	17	-2	24	12	-13	-0	12	-17	8	1
	47	35	24	14	1	3	584	21	-8	71	-76	51	52
YOY Profit Growth %	212.75%	-96.49%	-31.82%	-99.23%	-98.07%	-90.78%	2,333.33%	51.43%	-1,022.22%	2,115.63%	-113.08%	140.57%
EPS in Rs	0.39	0.29	0.20	0.12	0.01	0.03	4.88	0.18	-0.07	0.55	-0.57	0.32	0.32
Raw filing

Source: the company's results filed with NSE, as reported. EPS restated for bonus issues and splits. Tap a row marked + for its breakdown. Latest quarter on the right.

Profit & Loss

Consolidated figures in ₹ crore /

₹ Cr	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	5,514	6,367	7,106	8,184	11,174	14,756	15,262	16,927	17,321
YOY Sales Growth %		15.46%	11.60%	15.17%	36.54%	32.05%	3.43%	10.91%
	4,121	4,764	5,453	6,214	8,663	11,457	12,095	13,472	13,785
Material Cost %	34%	32%	31%	33%	33%	33%	34%	34%	33%
Employee Cost %	21%	23%	25%	23%	20%	18%	21%	21%	21%
Other Expenses %	19%	20%	21%	20%	25%	26%	25%	25%	26%
Operating Profit	1,394	1,603	1,653	1,970	2,512	3,299	3,166	3,455	3,536
OPM %	25%	25%	23%	24%	22%	22%	21%	20%	20%
	144	161	255	213	376	866	1,208	343	317
Exceptional items	195	68	13	-111	-291	-12	97	-403	-399
Interest	71	65	58	68	419	974	897	990	927
Depreciation	448	552	715	814	1,113	1,569	1,687	1,957	2,049
Profit before tax	1,214	1,215	1,147	1,190	1,064	1,609	1,887	448	479
	17%	26%	19%	18%	24%	14%	24%	18%	13%
Current tax	204	315	222	212	254	314	369	444
Deferred tax	9					-87	88	-365
	1,003	871	846	772	643	1,298	1,429	369	416
Profit from associates	1	-29	-70	-207	-167	-84
Minority share	-97	123	106	123	180	275	416	-17	-79
Profit to shareholders	905	748	741	648	463	1,023	1,013	386	495
YOY Profit Growth %		-13.14%	-2.84%	-8.82%	-16.67%	101.84%	10.14%	-74.20%
EPS in Rs	7.65	6.32	6.24	5.44	3.88	8.55	8.46	2.82	3.40
Dividend Payout %					16%	20%	8%	24%

Compounded Sales Growth

5 Years:: 19%
3 Years:: 15%
TTM:: 10%

Compounded Profit Growth

5 Years:: -15%
3 Years:: -17%
TTM:: -37%

Stock Price CAGR

5 Years:: 0%
3 Years:: 11%
1 Year:: -3%

Return on Equity

4 Years:: 4%
Last Year:: 1%

₹ Cr	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	2,885	1,988	2,028	1,738	1,993	2,127	2,243	2,346	2,434
YOY Sales Growth %		-31.07%	2.01%	-14.31%	14.65%	6.74%	5.42%	4.63%
	2,499	1,702	1,716	1,677	1,969	1,865	2,067	2,120	2,168
Material Cost %	44%	42%	39%	46%	49%	44%	46%	46%	45%
Employee Cost %	18%	17%	19%	21%	22%	21%	22%	20%	20%
Other Expenses %	25%	27%	26%	29%	28%	22%	24%	25%	24%
Operating Profit	386	286	313	61	24	263	176	226	266
OPM %	13%	14%	15%	4%	1%	12%	8%	10%	11%
	118	202	150	187	271	193	242	320	323
Exceptional items	199	160			2,863	15	608	-215	-215
Interest	3	1	0	0	70	199	237	142	104
Depreciation	147	98	104	108	117	121	128	137	142
Profit before tax	552	548	359	140	2,971	150	661	51	129
	11%	20%	22%	38%	4%	21%	8%	27%	24%
Current tax	59	112	78	54	123	15	31	12
Deferred tax						16	21	2
	493	441	281	86	2,848	119	609	37	98
YOY Profit Growth %		-10.51%	-36.38%	-69.30%	3,208.25%	-95.81%	410.73%	-93.89%
EPS in Rs	4.17	3.72	2.36	0.72	23.87	1.00	5.09	0.27	0.62
Dividend Payout %					3%	170%	14%	244%

Compounded Sales Growth

5 Years:: 3%
3 Years:: 6%
TTM:: 7%

Compounded Profit Growth

5 Years:: -33%
3 Years:: -76%
TTM:: -84%

Stock Price CAGR

5 Years:: 0%
3 Years:: 11%
1 Year:: -3%

Return on Equity

4 Years:: 4%
Last Year:: 1%

Financial years ending March; TTM = the last four quarters. Source: the company's results filed with NSE, as reported. EPS restated for bonus issues and splits. Tap a row marked + for its breakdown. Dividend payout = dividends paid in the year ÷ net profit.

Balance Sheet

Consolidated figures in ₹ crore, as at 31 March

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	600	600	600	811
Reserves	17,267	19,183	21,044	33,221
	18,019	16,277	18,362	15,434
Long term borrowings	15,291	12,932	12,405	10,746
Short term borrowings	2,480	2,797	5,350	4,078
	16,157	20,010	18,791	14,185
Trade payables	3,842	6,272	6,549	6,772
Minority interest	4,622	5,491	6,069	2,590
Current liabilities	8,511	15,359	14,334	14,069
Total Liabilities	52,043	56,071	58,797	63,651
	10,123	12,208	13,608	14,734
Gross block	15,240	18,123	20,404	22,724
Accumulated depreciation	5,117	5,915	6,796	7,990
Goodwill & intangibles	26,662	26,659	27,058	28,809
CWIP	2,588	4,216	4,295	4,683
	39,333	39,647	40,894	44,233
Inventories	4,244	4,944	4,931	6,086
Trade receivables	3,573	6,231	5,488	5,987
Cash & equivalents	1,323	1,233	3,227	2,416
Current assets	12,334	15,179	16,286	17,180
Total Assets	52,043	56,071	58,797	63,651

Source: Yahoo Finance (compiled from the annual reports). Tap a row marked + for its breakdown.

Cash Flows

Consolidated figures in ₹ crore, financial years ending March

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	1,853	2,954	4,061	1,994
Profit for the year	463	1,023	1,013	386
Working capital changes	-501	-635	923	-1,132
Direct taxes paid	-229	-292	-460	-243
	-14,282	-1,005	-234	-2,082
Fixed assets purchased	-1,726	-1,932	-2,343	-1,912
Fixed assets sold	3	23	0
Investments purchased	-18,714	-5,334	-10,242	-23,536
Investments sold	18,250	6,646	10,408	23,217
	13,049	-2,333	-1,854	-924
Proceeds from borrowings	10,940	1,372	10,343	301
Repayment of borrowings	-28	-2,768	-9,770	-2,708
Interest paid	-486	-847	-634	-865
Dividends paid	-72	-203	-83	-91
Net Cash Flow	619	-383	1,973	-1,012
Free Cash Flow	126	1,022	1,718	82

Free cash flow = cash from operations − capital expenditure. Source: Yahoo Finance.

Ratios

Ratio	Mar 2023	Mar 2024	Mar 2025	Mar 2026
ROE	2.6%	5.4%	4.9%	1.4%
ROCE	3.0%	6.1%	6.2%	2.8%
Operating margin	14.9%	10.1%	10.8%	10.3%
Net margin	4.2%	7.2%	6.7%	2.3%
Debt / equity	1.01	0.82	0.85	0.45
Current ratio	1.45	0.99	1.14	1.22
Debtor days	119	160	133	130
Inventory days	422	368	346	390
Days payable	382	467	460	434
Cash conversion cycle	159	61	19	86
Working capital days	128	-5	47	68

Computed from the reported statements: ROE on average equity; ROCE = EBIT / (total assets − current liabilities). Debtor days = receivables ÷ sales × 365; inventory and payable days use cost of goods sold; cash conversion cycle = debtor + inventory − payable days; working capital days = (current assets − current liabilities) ÷ sales × 365.

Shareholding Pattern

Numbers in percentages · as filed with NSE each quarter

Promoters 44.68%
FIIs 8.14%
DIIs 23.38%
Public 23.75%

%	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Promoters	60.64%	60.64%	60.64%	60.64%	60.64%	60.64%	60.64%	54.45%	54.45%	54.45%	44.91%	44.68%
	7.96%	6.55%	5.63%	5.90%	5.93%	5.66%	5.66%	6.04%	6.61%	7.39%	7.52%	8.14%
Foreign portfolio investors (Cat. I)	7.29%	6.06%	5.18%	5.50%	5.72%	5.43%	5.44%	5.79%	6.38%	7.12%	7.19%	7.78%
Foreign portfolio investors (Cat. II)	0.68%	0.49%	0.45%	0.40%	0.21%	0.23%	0.23%	0.25%	0.23%	0.27%	0.33%	0.36%
	14.08%	14.51%	13.68%	14.30%	14.44%	15.37%	15.72%	22.82%	22.10%	21.71%	24.07%	23.38%
Mutual funds	8.26%	9.31%	8.57%	8.69%	7.97%	8.58%	8.77%	15.24%	14.13%	13.75%	16.53%	15.47%
Insurance companies	5.76%	5.12%	5.01%	5.51%	6.23%	6.43%	6.55%	6.79%	7.08%	6.90%	6.16%	6.37%
Banks			0.01%	0.02%	0.02%				0.04%	0.01%	0.08%	0.10%
Alternative investment funds	0.06%	0.08%	0.10%	0.07%	0.22%	0.35%	0.41%	0.80%	0.81%	1.01%	1.24%	1.38%
	16.92%	17.96%	19.73%	18.89%	18.75%	18.12%	17.76%	16.50%	16.69%	16.33%	23.41%	23.75%
Retail (up to ₹2 lakh)	8.23%	9.00%	9.79%	8.94%	8.71%	8.35%	8.00%	7.39%	7.39%	7.16%	5.77%	5.84%
HNIs (above ₹2 lakh)	5.38%	5.47%	5.74%	5.70%	5.86%	5.72%	5.63%	5.19%	5.33%	5.23%	4.23%	4.42%
NRIs	0.63%	0.69%	0.83%	0.83%	0.74%	0.72%	0.75%	0.69%	0.71%	0.72%	0.60%	0.62%
Bodies corporate	0.90%	1.04%	1.46%	1.50%	1.47%	1.38%	1.46%	1.48%	1.63%	1.64%	6.17%	6.15%
IEPF	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%
No. of Shareholders	4,15,046	4,34,339	4,70,261	4,43,513	4,39,503	4,27,705	4,24,297	4,28,131	4,13,191	3,94,279	3,86,593	3,92,833

Source: shareholding patterns filed by the company with NSE. Public = non-institutional holders. Tap a row marked + for its breakdown.

Mutual funds & institutions holding Biocon

Holder (above 1%)	Stake
Magnum Hybrid Long Short FundMutual fund	8.75%
Life Insurance Corporation Of IndiaInsurance	3.73%
Isif Equity Ex-Top 100 Long-Short FundMutual fund	1.46%
Kotak Mahindra Trustee Co Ltd A/C Kotak Nifty MidcMutual fund	1.29%
Hdfc Life Insurance Company LimitedInsurance	1.01%

As named in the shareholding pattern for Jun 2026 filed with NSE; mutual funds together hold 15.47% of the company. Shareholders below 1% are not named in the filing.

Documents

Announcements

All announcements on NSE →

Annual reports

Credit ratings

Concalls & investor meets

Filings made by the company with NSE; documents open on NSE's website.

Key dates

Results announced: 11 Nov 2026
Ex-dividend date: 3 Jul 2026
Latest quarter: 30 Jun 2026
Financial year end: 31 Mar 2026

Trade with our broking desk

Open a trading & demat account through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539; NSE AP0153037862, BSE AP01095201177059). Execution and service only: no tips or research.

Open an account How it works

Latest news

In the news

BIOCON Outlook for the WeekEquitypandit · 9 Oct 2026

From the company (NSE)

Headlines from news publishers (via Google News) and the filings of the company with NSE; they open on the source website. Headlines with price targets or buy/sell calls are left out. News is for information only and is not a recommendation.

Questions about Biocon Limited

What is the share price of Biocon Limited today?

Biocon Limited (BIOCON) last traded at ₹349.20 on NSE (16 Oct 2026, 3:28 PM IST). Prices may be delayed.

What is the market cap of Biocon Limited?

About ₹57,190 crore at the latest price.

What is the P/E ratio of Biocon Limited?

About 103.3 times its earnings over the last 12 months.

Is Biocon Limited a good investment?

We do not give views on individual shares. Whether any share suits you depends on your goals, time horizon and risk appetite; for long-term goals, a diversified mutual fund is often a simpler way to own shares. Investments in securities markets are subject to market risks.

How can I buy Biocon Limited shares?

You need a trading and demat account with a SEBI-registered stock broker. We can help you open one through Parshvanath Investments, an Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539). We provide execution and account service only, not tips or research.

Important. Prices from NSE via Yahoo Finance. Quarterly and annual results, shareholding and documents are taken from the filings the company made with NSE; balance sheet, cash flow and valuation figures are compiled by Yahoo Finance; ratios are computed by us from them. Figures may be delayed or revised. This page is for information only: it is not research, a recommendation or an offer to buy or sell any security. Investments in securities markets are subject to market risks; read all related documents carefully before investing. Plenitude Connect Private Limited is an AMFI-registered Mutual Fund Distributor (ARN-130934); share broking is offered through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539).

Talk to us

Have a question about this topic?

Tell us a little about your situation and an expert will call you back, usually within 2 hours on business days.

Get in touch

We typically respond within 2 hours on business days.

Call us

CA Amit Kumar Jain+91 93522 44475 Arihant Jain+91 80056 49698 Poornima Jain+91 92525 44475

Email ussupport@plenitude.co.in

WhatsAppChat with an expert

Visit us5C, Laxmi Colony, Near Bohra Ji Ka Bagh, Opp. Laxmi Mandir Cinema, Tonk Road, Jaipur, Rajasthan 302015

Mon–Sat · 10:00 AM – 7:00 PM IST

In your free consultation

A health check of your current investments
A goal-based plan for retirement, education or a home
Ways to save tax that fit your situation
Clear next steps, with zero pressure to invest

2,000+Investors

₹250 Cr+Client assets

15+ yrsExperience

AMFI Registered Mutual Fund Distributor · ARN-130934

Experts are available Mon–Sat, 10 AM – 7 PM

Book your free wealth consultation

100% free
No obligation
Reply within 2 hours

First name *

Last name *

Email *

Phone *

+91

I'm interested in *

Best day for a call

Preferred time

How can we help? (optional)

Upload your portfolio (optional, get a free expert review)Attach your portfolio statement · PDF, Excel or CSV (e.g. CAS), max 10 MB

I consent to being contacted by Plenitude Connect about financial services. My data will be handled as per the Privacy Policy.

Join 2,000+ investors who plan with Plenitude

Your details are private and never shared.

Biocon Limited share price

Price chart

Quick take

Pros

Cons

AI analysis

About Biocon Limited

Peer comparison

Quarterly Results

Profit & Loss

Projection — your assumptions

Related party transactions

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Balance Sheet

Cash Flows

Ratios

Shareholding Pattern

Mutual funds & institutions holding Biocon

Documents

Announcements

Annual reports

Credit ratings

Concalls & investor meets

Key dates

Trade with our broking desk

Latest news

In the news

From the company (NSE)

Questions about Biocon Limited

Have a question about this topic?

Book your free wealth consultation

Request received!

What happens next